Nyxoah (NYXH) Projected to Post Earnings on Tuesday

Key Points

• Q1 2026 results are due before the market opens on Tuesday, May 12, 2026, with analysts forecasting earnings of ($0.54) per share, revenue of $7.049 million, and a conference call scheduled for 4:30 PM ET.
• Nyxoah remains unprofitable—its last quarter showed a ($0.69) EPS and $6.62 million revenue, and analysts expect roughly - $2 EPS for both the current and next fiscal years while the stock trades near $2.93 with a market cap of about $113.6 million.
• Analyst sentiment is mixed but generally positive: the consensus rating is "Moderate Buy" with an average price target of $9.33, while recent broker actions include Stifel lowering its target to $8, Cantor Fitzgerald at $11, and Weiss issuing a downgrade.

Nyxoah (NASDAQ:NYXH - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Nyxoah to post earnings of ($0.54) per share and revenue of $7.0490 million for the quarter. Interested persons may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.69) EPS for the quarter. The business had revenue of $6.62 million for the quarter. Nyxoah had a negative return on equity of 139.18% and a negative net margin of 884.69%. On average, analysts expect Nyxoah to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Nyxoah Stock Up 1.7%

Shares of NASDAQ NYXH traded up $0.05 during mid-day trading on Tuesday, reaching $2.93. 29,815 shares of the company's stock were exchanged, compared to its average volume of 49,186. The firm has a market capitalization of $113.57 million, a price-to-earnings ratio of -1.09 and a beta of 1.56. The company has a current ratio of 1.25, a quick ratio of 1.16 and a debt-to-equity ratio of 0.37. The business has a fifty day simple moving average of $3.38 and a 200 day simple moving average of $4.38. Nyxoah has a twelve month low of $2.76 and a twelve month high of $8.64.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NYXH. Stifel Nicolaus dropped their price objective on shares of Nyxoah from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, April 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $11.00 price objective on shares of Nyxoah in a report on Monday, March 23rd. Finally, Weiss Ratings downgraded Nyxoah from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, April 22nd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $9.33.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE boosted its stake in shares of Nyxoah by 72.4% during the 2nd quarter. Bank of America Corp DE now owns 7,866 shares of the company's stock worth $59,000 after acquiring an additional 3,303 shares during the period. Raymond James Financial Inc. bought a new position in shares of Nyxoah during the 2nd quarter worth approximately $70,000. Citadel Advisors LLC bought a new position in shares of Nyxoah during the 3rd quarter worth approximately $98,000. Deutsche Bank AG lifted its position in shares of Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company's stock worth $161,000 after buying an additional 10,000 shares during the last quarter. Finally, Shay Capital LLC bought a new stake in shares of Nyxoah during the 2nd quarter worth $374,000.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company's primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.